Tumor imaging using a picomolar affinity HER2 binding affibody molecule.

@article{Orlova2006TumorIU,
  title={Tumor imaging using a picomolar affinity HER2 binding affibody molecule.},
  author={Anna Orlova and Mikaela Magnusson and Tove L. J. Eriksson and Martin Nilsson and Barbro Larsson and Ingmarie H{\"o}id{\'e}n-Guthenberg and Charles Widstr{\"o}m and J{\"o}rgen Carlsson and Vladimir M. Tolmachev and Stefan Ståhl and Fredrik Y Nilsson},
  journal={Cancer research},
  year={2006},
  volume={66 8},
  pages={
          4339-48
        }
}
The detection of cell-bound proteins that are produced due to aberrant gene expression in malignant tumors can provide important diagnostic information influencing patient management. [] Key Method A library for affinity maturation was constructed by re-randomization of relevant positions identified after the alignment of first-generation variants of nanomolar affinity (50 nmol/L). One selected Affibody molecule, Z(HER2:342) showed a >2,200-fold increase in affinity achieved through a single-library affinity…
View on PubMed
cancerres.aacrjournals.org
453 Citations
Highly Influential Citations
28
Background Citations
159
Methods Citations
50
Results Citations
15

Figures and Tables from this paper

453 Citations

Citation Type

Citation Type

Tumor Targeting Using Affibody Molecules: Interplay of Affinity, Target Expression Level, and Binding Site Composition
TLDR
The optimal affinity of HER2-binding Affibody molecules depends on the expression of a molecular target, and at a high expression level (>106 receptors per cell), an affinity in the low-nanomolar range is sufficient.
Radiolabeled HER-2 Binding Affibody Molecules for Tumor Targeting : Preclinical Studies
TLDR
Two affibody variants were shown to selectively bind to the extracellular domain of HER2/neu (HER2-ECD), but not to control proteins, which might be considered in tumor targeting applications for radionuclide diagnostics and therapy of adenocarcinomas such as breast and ovarian cancers.
64Cu-Labeled Affibody Molecules for Imaging of HER2 Expressing Tumors
TLDR
This study demonstrates that 64Cu-labeled ZHER2:477 is a promising targeted molecular probe for imaging HER2 receptor expression in living mice and improves the dosimetry and imaging efficacy, of the radiometal-based probe.
Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy
TLDR
Preclinical studies have demonstrated the potential of Affibody molecules for specific and high-contrast radionuclide imaging of HER2 in vivo, and pilot clinical data using indium-111 and gallium-68 labeled anti-HER2Affibody tracer have confirmed its utility for radion UCLA imaging in cancer patients.
PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules
TLDR
The goal was to optimize the radiolabeling method of this affibody molecule with Cu-64, and translate a positron emission tomography (PET) probe with the best in vivo performance to clinical PET imaging of HER2-positive cancers.
Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand.
Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule.
Molecular Design and Optimization of 99mTc-Labeled Recombinant Affibody Molecules Improves Their Biodistribution and Imaging Properties
TLDR
99mTc-ZHER2:V2 is a promising candidate for further development as a diagnostic radiopharmaceutical for imaging of HER2-expressing tumors and may be useful for the development of imaging agents based on other Affibody molecules and, hopefully, other scaffolds.
Affibody Molecules for In vivo Characterization of HER2-Positive Tumors by Near-Infrared Imaging
TLDR
The results suggest that Affibody-Alexa Fluor conjugates may be used as a specific NIR probe for the noninvasive semiquantitative imaging of HER2 expression in vivo.
Radiolabeling of HER2 specific Affibody(R) molecule with F-18.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 55 REFERENCES
In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics.
TLDR
A bivalent form of the affibody ligand, (Z(HER2:4), with approximately the same affinity as the monoclonal antibody trastuzumab (Herceptin) but only one tenth of the size, is a promising candidate for radionuclide-based detection of HER-2 expression in tumors.
Selection and characterization of HER2/neu-binding affibody ligands.
TLDR
Two affibody variants were shown to selectively bind to the extracellular domain of HER2/neu (HER2-ECD), but not to control proteins, which might be considered in tumor targeting applications for radionuclide diagnostics and therapy of adenocarcinomas such as breast and ovarian cancers.
Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice
TLDR
The results indicate that the (ZHER2:4)2 affibody is an interesting candidate for applications in nuclear medicine, such as radionuclide-based tumour imaging and therapy.
Imaging tumors with peptide-based radioligands.
  • T. Behr, M. Gotthardt, A. Barth, M. Béhé
  • Biology, Medicine
    The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology
  • 2001
TLDR
This review aims to give an overview of the peptide-based radiopharmaceuticals which are presently already commercially available or which are in advanced stages of their clinical testing so that their broader availability is anticipated soon.
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.
TLDR
By manipulating the size and format of anti-p185(HER2) antibody fragments, the kidney activity was reduced and high or low expression of p185HER2 in xenografts could be distinguished by microPET imaging.
Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII‐specific scFv
TLDR
The improved affinity of MR1‐1 can significantly impact in vivo glioma‐specific targeting and immunotherapy and its rapid clearance from normal tissues also resulted in sustained higher tumor:normal organ ratios.
Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody.
TLDR
Diabodies may represent an effective molecular structure for development of novel PET radiotracers for oncologic PET imaging and quantitation of the tumor targeting by PET correlated with traditional necropsy-based analysis at all time points analyzed.
Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu.
TLDR
The diabody format provides the C6.5 molecule with a distinct in vitro and in vivo targeting advantage and has promise as a delivery vehicle for therapeutic agents.
Pharmacokinetics and biodistribution of genetically-engineered antibodies.
Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
TLDR
The construction of bivalent diabody molecules from three affinity mutants of the human anti-ErbB2 (HER2/neu) scFv molecule C6.5 concluded that, above a threshold affinity, other factors regulate quantitative tumor retention.
...
1
2
3
4
5
...